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        DCs are professional APCs that activate na-
ive T cells, and thereby control the initiation 
of adaptive immune responses (  1, 2  ). Several 
types of DC, varying in hematopoietic origin, 
surface phenotype, and function, have been 
described (  3, 4  ). The two major groups are the 
CD11c  int  CD45R     plasmacytoid DCs (pDCs), 
which are characterized by their high capacity 
to secrete type I IFN (  5  ), and the CD11c  high 
CD45R        conventional DCs (cDCs), which 
play major roles in T cell priming (  6, 7  ). One 
recently described DC type is the IFN-producing 
killer DC (IKDC), which has been proposed 
to provide a link between innate and adap-
tive immune responses (  8, 9  ). IKDCs resemble 
cells of the innate immune system by lysing NK 
cell targets and producing large amounts of 
IFN-     (  8  –  10  ), although in contrast with   previous 
reports we recently found they do not pro-
duce IFN-     (  10  ). Upon activation, IKDCs have 
been claimed to up-regulate MHC class II and 
acquire the ability to present antigen-like cDCs, 
thereby directing adaptive T cell responses (  9  ). 
Related hybrid cells have been previously de-
scribed in mice (  11, 12  ), rats (  13  –  15  ), and hu-
mans (  16  –  18  ), and although the phenotypic 
defi  nition varies between reports, dual func-
tion remains the central theme. In humans, 
the converse situation of NK cells that behave 
like DCs has been demonstrated; human NK 
cells have been shown on activation to express 
MHC class II, and then to process and present 
antigen to T cells (  19  –  21  ). Such conversion of 
NK cells into APCs has not been demonstrated 
in mice (  22  ). 
  In the studies proposing a dual function (  8, 9  ), 
the IKDCs were initially found to express in-
termediate levels of the DC marker CD11c, 
CORRESPONDENCE  
 Irina  Caminschi: 
 caminschi@wehi.edu.au
  Abbreviations used: cDC, con-
ventional DC; CHO, chinese 
hamster ovary; IKDC, IFN-
producing killer DC; pDC, 
plasmacytoid DC; PI, propid-
ium iodide; SA, streptavidin. 
      The online version of this article contains supplemental material.   
  Putative IKDCs are functionally 
and developmentally similar to natural 
killer cells, but not to dendritic cells 
  Irina Caminschi,  1   Fatma Ahmet,  1   Klaus Heger,  1   Jason Brady,  1   
Stephen L. Nutt,  1   David Vremec,  1   Suzanne Pietersz,  1   Mireille H. Lahoud,  1   
Louis Schofi  eld,  1   Diana S. Hansen,  1   Meredith O  ’  Keeff  e,  2   Mark J. Smyth,  3   
Sammy Bedoui,  1   Gayle M. Davey,  1   Jose A. Villadangos,  1   William R. Heath,  1   
and Ken Shortman  1   
  1  The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, 3050, Australia 
  2  Bavarian Nordic GmbH, Munich D-82152, Germany 
  3  Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, 3002, Victoria, Australia   
  Interferon-producing killer dendritic cells (IKDCs) have been described as possessing the 
lytic potential of NK cells and the antigen-presenting capacity of dendritic cells (DCs). In 
this study, we examine the lytic function and antigen-presenting capacity of mouse spleen 
IKDCs, including those found in DC preparations. IKDCs effi  ciently killed NK cell targets, 
without requiring additional activation stimuli. However, in our hands, when exposed to 
protein antigen or to MHC class II peptide, IKDCs induced little or no T cell proliferation 
relative to conventional DCs or plasmacytoid DCs, either before or after activation with 
CpG, or in several disease models. Certain developmental features indicated that IKDCs 
resembled NK cells more than DCs. IKDCs, like NK cells, did not express the transcription 
factor PU.1 and were absent from recombinase activating gene-2  –  null, common     -chain  –
  null (Rag2      /     Il2rg      /     ) mice. When cultured with IL-15 and -18, IKDCs proliferated exten-
sively, like NK cells. Under these conditions, a proportion of expanded IKDCs and NK cells 
expressed high levels of surface MHC class II. However, even such MHC class II     IKDCs 
and NK cells induced poor T cell proliferative responses compared with DCs. Thus, IKDCs 
resemble NK cells functionally, and neither cell type could be induced to be effective 
antigen-presenting cells. 2580 IKDCS ARE POOR ANTIGEN-PRESENTING CELLS | Caminschi et al.
CD11c, but unlike pDCs, they also express CD49b (DX5) 
and NK1.1 (  8, 9  ). Using our DC isolation procedure that 
enriches for splenic pDCs and cDCs (  Fig. 1 A  ), we noted that 
a proportion of cells expressed CD49b (  Fig. 1 B  ).   These 
CD49b     cells expressed variable levels of CD45R (and 
CD45RA; not depicted), ranging from undetectable to high 
(  Fig. 1 C  ). Furthermore, the majority of CD49b     cells ex-
pressed low to intermediate levels of CD11c, although a small 
proportion were CD11c  hi   (  Fig. 1 C  ). The subpopulation of 
the CD49b     cells that were CD11c  int  CD45R     therefore 
matched the description of IKDCs (  Fig. 1 C  ). Additionally, 
there appeared to be another minor population of CD49b     
cells that expressed high levels of CD11c and MHC class II, 
like cDCs; we termed these CD49b    DCs. Further analysis 
showed that these IKDCs and NK cells, but not CD49b    cDCs, 
pDCs, or cDCs, expressed NKG2D and NK1.1 (  Fig. 1 D  ). 
The freshly isolated IKDCs expressed only low levels of MHC 
class II (  Fig. 1 D  ), as previously reported (  9  ). However, the 
level appeared a little lower than in the earlier study, which 
may refl  ect diff  erences in reagents and staining strategies, or 
diff  erences in the IKDC isolation procedures. 
to express CD45R like pDCs and NK cells, and to express 
CD49b like NK cells, but to have low surface MHC class II 
expression. We have identifi  ed cells with this surface pheno-
type and isolated them from our DC preparations, as well as 
from the total spleen population. The IKDCs that we isolated 
were immediately capable of killing NK cell targets, but in 
response to CpG and a range of other stimuli, failed to up-
regulate MHC class II and failed to effi   ciently activate naive 
T cells. In terms of developmental requirements and functional 
capacity, the IKDCs that we isolated resembled NK cells 
rather than DCs. Importantly, we show that mouse IKDCs 
and NK cells proliferated, and a proportion up-regulated 
MHC class II molecules upon exposure to IL-15 and -18 in 
cell culture, in this respect aligning mouse and human NK cell 
biology; however, both cell types in our hands remained poor 
activators of naive T cells. 
    RESULTS   
  Surface phenotype analysis 
  IKDCs have been defi  ned as cells that are similar to pDCs in 
that they express CD45R (B220) and intermediate levels of 
  Figure 1.     Surface phenotype of IKDCs. Splenic DCs were isolated and enriched as described in the Materials and methods. The enriched DC prepara-
tion was stained with anti-CD11c-Cy7-PE, anti-CD45R (B220-FITC), and anti-CD49b (DX5-biotin), followed by the secondary reagent SA-Alexa Fluor 594, 
and then analyzed by fl  ow cytometry. Dead cells were stained with PI. (A) Gating for cDCs (CD11c  hi CD45R      ) and pDCs (CD11c  int CD45R   ) without exclud-
ing CD49b     cells. (B) Gating for CD49b     within the DC-enriched preparation. (C) Expression of CD11c and CD45R on the CD49b     cells, showing the gates 
used for IKDC and CD49b    DC isolation. (D) The expression of NK1.1, NKG2D, and MHC class II on splenic DC subsets. For NK1.1 expression analysis, 
splenic DC preparations were stained with anti-NK1.1 (PK136-APC), anti-CD45R (B220-PE), anti-MHC class II (M5/114-FITC), anti-CD11c (N418-Alexa 
Fluor 594), and anti-CD49b (DX5-biotin; followed by secondary reagent SA-Cy7PE). For NKG2D expression analysis, splenic DC preparations were stained 
with anti-NKG2D (CX5-biotin), anti-CD49b (DX5-FITC), anti-CD11c (N418-Alexa Fluor 594), and anti-CD45R (B220-PE), followed by SA-Cy7-PE secondary 
reagent. For MHC class II expression analysis, splenic DC preparations were stained with anti-MHC class II (M5/114-FITC), anti-NK1.1 (P136-APC), 
anti-CD11c (N418-Alexa-594), and anti-CD45R (B220-PE). Based on the expression of CD11c, CD45R, and CD49b, subsets were defi  ned as IKDC 
(CD11c  int CD45R  CD49b  ),  CD49b  DC  (CD11c hi CD49b   ), pDC (CD11c  int CD45R  CD49b       ), and cDC (CD11c  hi CD45R     CD49b      ). Spleen suspensions, 
which were depleted of red blood cells using 1.091 g/cm  3   Nycodenz density centrifugation, were the source of NK cells. Splenocytes were stained with 
anti-NK1.1 (PK136-APC), anti-CD49b (DX5-Biotin; followed by secondary reagent SA-Cy7-PE), and anti-CD3 (KT3-Alexa-594), then NK cells sorted as 
NK1.1   CD49b  CD3      . The continuous line represents staining on gated cells and the dotted line represents background.     JEM VOL. 204, October 29, 2007 
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However, culturing our purifi  ed IKDCs with CpG and GM-
CSF for 48 h resulted in   <  10% survival (  Fig. 4 A  ), despite the 
presence of GM-CSF, which enhances the in vitro survival 
of cDC.   This questioned the origin of the few remaining cells 
because the starting cultures of IKDCs were 95% pure, with 
5% of cells likely to be DC contaminants. To circumvent 
problems associated with poor IKDC survival in culture, we 
isolated IKDCs and pDCs from transgenic mice expressing 
  Lytic function of IKDCs 
  The initial study describing IKDCs suggested that preincuba-
tion with CpG was required for induction of lytic capacity (  9  ). 
Al  though we confi  rmed that IKDCs (CD11c  int  CD45R   
CD49b    ) killed YAC-1 target cells after incubation with CpG 
and GM-CSF (not depicted), we observed, in contrast to the 
previous study, that even freshly isolated IKDCs (but not pDCs 
or cDCs) also effi   ciently killed YAC-1 (  Fig. 2 A  ) or chinese 
hamster ovary (CHO)-K1-OVA (  Fig. 2, B and C  ) cells.   The 
lytic activity of IKDCs was comparable to, or even slightly 
better than, that of NK cells (  Fig. 2  ). Those CD11  int  CD49b     
cells, which expressed lower levels of CD45R, also killed 
these NK cell  –  sensitive target cells (unpublished data). 
  T cell stimulation capacity 
  To assess our isolated IKDCs for their ability to present anti-
gen and activate naive T cells, which is a hallmark of DCs, we 
compared them to cDCs, pDCs, and NK cells by coculturing 
each population with MHC class II  –  restricted, OVA-specifi  c 
CD4 T cells (OT-II) in the presence of whole OVA protein 
or doses of OVA peptide up to and beyond the optimum for 
cDCs. The proliferative response of CFSE-labeled OT-II cells 
was enumerated 3 or 5 d later. We also compared the eff  ects of 
adding CpG (1668) to the cultures, as this had been identifi  ed 
as a factor that matures IKDCs in vitro to become APCs (  9  ). 
However, our B6 IKDCs failed to induce OT-II proliferation 
to either the whole protein or to the peptide, whereas cDCs 
induced potent proliferative responses and pDCs induced 
moderate responses (  Fig. 3, A and C  ).   Coculture in the pres-
ence of CpG and GM-CSF did not enhance the stimulatory 
capacity of IKDCs (  Fig. 3, B and D  ). Similar results were ob-
tained when we isolated IKDCs from BALB/c mice and used 
these as APCs (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20071351/DC1). The lack of APC 
function was also observed when B6 DCs were fi  rst preincu-
bated overnight with CpG and GM-CSF, and then sorted for 
IKDCs (Fig. S2). 
  Because CpG failed to enhance antigen presentation 
by IKDCs in our studies, we checked the reported capacity 
of CpG to up-regulate MHC class II on these cells (  9  ). 
  Figure 2.     IKDCs kill YAC-1 and CHO-K1 target cells. Splenic DCs were enriched and sorted based on their expression of CD11c, CD45R, and CD49b, 
as described in the Materials and methods. CD11c  hi CD45R       (cDC),  CD11c int CD45R  CD49b       (pDC), and CD11  int CD45R  CD49b    (IKDC) were purifi  ed and 
incubated at various ratios with   51  Cr-labeled YAC-1 (A) and CHO-OVA (B) target cells in a 4-h   51  Cr release assay, or in a 5-h   51  Cr release assay at an E/T 
ratio of 2:1 (C). Lysis at each effector to target (E/T) cell ratio was determined as described in the Materials and methods. Each assay point was done in 
triplicate or duplicate, and the result is representative of a minimum of two experiments. Error bars indicate the SEM.     
  Figure 3.     IKDCs cultured in the presence of OVA protein or peptide 
do not induce naive OVA-specifi  c transgenic T cells to proliferate. 
Splenic pDCs (CD11c  int CD45R  CD49b      ), cDCs (CD11c  hi CD45R     CD49b     ), 
IKDCs (CD11c  int CD45R  CD49b   ), and NK cells (CD49b   NK1.1  CD3     ) 
were isolated and purifi  ed by fl  ow cytometry. The purifi  ed cells (10  4 )  were 
cocultured for 3 d (A and B) with graded doses of class II  –  restricted 
OVA  323-339   peptide and 5      10 4   CFSE-labeled OT-II cells in the absence 
(A) or presence (B) of CpG and GM-CSF. APCs and CFSE-labeled OT-II cells 
were also incubated for 3 and 5 d with 0.5 mg/ml whole OVA protein in 
the absence (C) or presence (D) of CpG and GM-CSF. The proliferative 
response of OT-II cells was enumerated by fl  ow cytometry, as described in 
the Materials and methods. Sample points were prepared in duplicates, 
and results are representative of several experiments.     2582 IKDCS ARE POOR ANTIGEN-PRESENTING CELLS | Caminschi et al.
compared with cDCs (  Fig. 6, A and B  ).   Thus, in vitro infection 
with virus did not enhance the ability of IKDCs to stimulate 
naive T cells to proliferate. 
  In the third model, we examined IKDCs in mice infected 
with malaria (  Plasmodium berghei  ). We observed that such mice 
had increased numbers of IKDCs in the spleen (Fig. S3, available 
at http://www.jem.org/cgi/content/full/jem.20071351/DC1). 
Furthermore, infection with   P. berghei   results in systemic DC 
activation (  24  ). We reasoned that the factors that governed the 
Bcl-2 in their hematopoietic compartment (  23  ). Cells from 
these mice are more resistant to factor deprivation  –  induced 
cell death, and 80% survival of IKDCs could be achieved 
after 48 h of culture (  Fig. 4 A  ). Assessment of Bcl-2 transgenic 
IKDCs for up-regulation of MHC class II in response to 
CpG revealed no change in expression, although pDCs cul-
tured under identical conditions clearly up-regulated MHC 
class II (  Fig. 4 B  ). Similar experiments were performed using 
other stimulatory factors known to up-regulate MHC class II 
on DCs (LPS, IFN-    , IL-4, and poly I:C), but all failed to 
enhance MHC class II levels on IKDC (not depicted). 
  Thus, the IKDCs we isolated did not up-regulate MHC 
class II and become APCs under conditions known to up-
regulate MHC class II on DCs. However, it could not be 
excluded that under diff  erent conditions this might occur. 
Therefore, we attempted to activate IKDCs in three diff  erent 
experimental models. In the fi  rst, the IKDCs we isolated 
were incubated with target cells (CHO-OVA cells), which 
they effi   ciently kill (  Fig. 2 B  ). We reasoned that IKDCs might 
fi  rst have to fulfi  l their cytolytic function, which might then 
provide the impetus for maturation into DCs. IKDCs were 
cocultured with graded numbers of CHO-OVA cells and 
CFSE-labeled OT-I or OT-II cells in the presence or ab-
sence of CpG. 3 d later, the number of transgenic cells that 
had proliferated were enumerated. IKDCs failed to induce 
naive OT-II cell proliferation (  Fig. 5, A and B  ).   We also 
tested cross-presentation of OVA in this assay, by incubation 
with OT-I T cells, and this demonstrated that IKDCs did not 
have this capacity (  Fig. 5, C and D  ). However cDCs, which 
did not kill these target cells (  Fig. 2 C  ), were able to initiate 
T cell responses, presumably by presenting antigen from the 
few CHO-OVA cells that died in culture (  Fig. 5, C and D  ). 
  In the second model, sorted BALB/c IKDCs (purifi  ed us-
ing the same sorting gates as B6 IKDC;   Fig. 1  ) were infected 
in vitro with infl  uenza virus, and then cultured in the presence 
of CpG and CFSE-labeled infl  uenza-specifi  c transgenic CD4 
(HNT) and CD8 (CL4) T cells for 3 d. Under these conditions, 
BALB/c IKDCs induced only minimal T cell proliferation 
  Figure 4.     IKDCs stimulated with CpG do not up-regulate MHC-class II and normally die in culture. IKDC and pDCs were isolated from B6 and 
Bcl-2 transgenic B6 mice. Cells (1  –  2      10 4  ) were cultured in the presence of CpG and GM-CSF (which enhances the survival of DCs). Cells were enumer-
ated and assessed for the level of MHC class II expression on day 0 and 2. (A) Percentage recovery of IKDCs and pDCs from B6 and Bcl-2 transgenic mice 
after 2 d in culture with CpG and GM-CSF. Data represents two pooled experiments, and the error bars indicate the SEM. (B) The levels of MHC class II 
expression before and after activation with CpG and GM-CSF using Bcl-2 transgenic cells to extend cell survival. The solid line represents staining on 
gated cells, and the dashed line represents background. Histograms presented are representative of three independent experiments.   
  Figure 5.     IKDCs fail to present the antigen of target cells that 
they have lysed. Splenic pDCs (CD11c  int CD45R  CD49b     ),  cDCs 
(CD11c  hi CD45R     CD49b      ), IKDCs (CD11c  int CD45R  CD49b   ), and NK cells 
(CD49b   NK1.1  CD3      ) were isolated and purifi  ed by fl  ow cytometry. These 
cells (10  4  ) were cocultured with graded numbers of CHO-OVA cells and 
either 5      10 4   CFSE-labeled OT-II (A and B) or OT-I (C and D) transgenic T 
cells in the absence (A and C) or presence (B and D) of CpG and GM-CSF. 
The proliferative response of the transgenic T cells was enumerated by 
fl  ow cytometry, as described in the Materials and methods. Sample points 
were prepared in duplicate, and the presented data is representative of a 
minimum of two experiments.     JEM VOL. 204, October 29, 2007 
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http://www.jem.org/cgi/content/full/jem.20071351/DC1). 
We also followed the Chan et al. (  9  ) procedure in using only 
anti-CD3 and -CD19 as depletion mAbs, but the IKDCs again 
failed to become eff  ective APCs (  Fig. S4 B  ). We also noted 
that some cells with the IKDC surface phenotype were denser 
than the 1.077 g/cm  3   used in this study and by Chan et al. (  9  ) 
to enrich DCs, although all IKDCs appeared less dense than 
1.082 g/cm  3  . To ensure we recovered all spleen cells with the 
surface phenotype of IKDCs, we isolated IKDCs using a much 
denser cut, which recovered all spleen-viable cells (eliminating 
only erythrocytes and dead cells), as well as omitting anti-Thy1.1 
mAb from the depletion mix. However, this   “  total  ”   IKDC 
fraction likewise failed to acquire APC function on culture 
with CpG (Fig. S4 C). We concluded that the behavior of the 
IKDCs in our DC-enriched preparations refl  ected that of the 
total IKDC population. 
  Absence of IKDC in Rag2      /     Il2rg      /      mice 
  The effi   cient lytic function of IKDC, but poor capacity 
to present antigen to naive T cells, suggested that IKDCs 
were a type of NK cell rather than a subtype of DCs. One 
important argument against this conclusion was the reported 
presence of IKDCs in recombinase-activating gene-2 null, 
common     -chain null (Rag2      /     Il2rg      /     ) mice, which are 
defi  cient in NK cells (  8, 25  ). Therefore, we reexamined this 
issue. We found that a major complication in the analysis 
of Rag2      /     Il2rg      /      mouse spleen is the high frequency of 
accumulation of IKDCs and systemic activation of DCs in 
the spleens of mice infected with malaria might also activate 
the antigen-presenting capacity of IKDCs. Thus, we isolated 
IKDCs from malaria-infected mice and assessed their ability 
to induce antigen-specifi  c CD4     T cell proliferation by cocul-
turing them with graded doses of MHC class II  –  restricted OVA 
peptide for 3 or 5 d. These IKDCs also failed to induce sig-
nifi  cant OT-II proliferation (  Fig. 6, C and D  ). In comparison, 
and consistent with the results shown in   Fig. 3  , cDCs cultured 
with OVA peptide induced potent OT-II proliferation, whereas 
pDCs induced more moderate proliferation, regardless of 
whether they were isolated from malaria-infected mice or 
healthy control mice (  Fig. 6, C and D  ). 
  T cell stimulatory capacity of total spleen IKDCs 
  It was possible our failure to activate IKDCs to become APCs 
was because we had isolated an IKDC population that was dif-
ferent from that of Chan et al. (  9  ), despite the similarities in the 
isolation procedure. One diff  erence was that, when depleting 
our DC preparations of lymphoid cells, we normally include 
several mAbs for maximum purity, including anti-CD90 
(Thy1.1; T24/31.7), which Chan et al. (  9  ) did not. Indeed, we 
found that     50% of IKDCs expressed CD90, and that some 
of these were likely removed from our IKDC sample. How-
ever, when CD90 depletion was omitted, the resulting IKDCs 
in our DC preparations still failed to become eff  ective APCs 
on activation with CpG (Fig. S2 B and Fig. S4 A, available at 
  Figure 6.     IKDCs exposed to two different pathogens do not acquire the ability to stimulate naive T cells into proliferation. Splenic pDCs 
(CD11c  int CD45R  CD49b      ), cDCs (CD11c  hi CD45R     CD49b      ), IKDCs (CD11c  int CD45R  CD49b   ), and NK cells (CD49b   NK1.1  CD3      ) were isolated and 
purifi  ed by fl  ow cytometry. (A and B) These cells were infected in vitro with infl  uenza (PR8 infl  uenza virus), washed, and used at the indicated numbers 
to stimulate fl  u-specifi  c transgenic CD4 (HNT; A) and CD8 (CL4) T cells (B). Proliferating T cells were identifi  ed and enumerated by fl  ow cytometry. 
(C and D) Mice were infected with malaria (  P. berghei  ) and killed 3 d later. Spleens from healthy or malaria-infected mice were used to isolate and purify pDCs 
(CD11c  int CD45R  CD49b      ), cDCs (CD11c  hi CD45R     CD49b      ), IKDCs (CD11c  int CD45R  CD49b +  ), and NK cells (CD49b   NK1.1  CD3      ), and 10  4   APCs were cocul-
tured for 3 (C) and 5 d (D) with graded doses of class II-restricted OVA  323-339   peptide and 5   ×   10  4   CFSE-labeled OT-II. Proliferating OT-II were enumerated 
as indicated in the Materials and methods. The presented data is representative of three independent experiments.     2584 IKDCS ARE POOR ANTIGEN-PRESENTING CELLS | Caminschi et al.
very few cells that had this phenotype (  Fig. 7 C  ). Because 
even these may have been residual autofl  uorescent cells or 
other noise, we then used the more stringent defi  nition that 
specifi  es IKDC to be NK1.1    , as well as CD49b    CD11c  int 
CD45R     (  Fig. 7 D  ), and found that these cells were at ex-
tremely low levels in Rag2      /     Il2rg      /      mice (  Fig. 7 E  ). Further-
more, the NK cell  –  sensitive targets RMA-S and RMA-S 
Rae-    , which are killed in a perforin- and NKG2D-depen-
dent manner (  27  ), were growth suppressed (RMA-S) and re-
jected (RMA-S Rae-    ) in Rag      /      mice, but not eliminated 
in Rag2      /     Il2rg      /      mice, or in Rag      /      mice depleted of 
NK1.1     cells (Fig. S5, available at http://www.jem.org/cgi/
content/full/jem.20071351/DC1). This argues that the residual 
CD49b     cells present in Rag2      /     Il2rg      /      mice are neither 
NK cells nor IKDCs, which have been shown to kill targets 
autofl  uorescent cells, which can generate false positives in the 
analysis of rare DC populations (  10  ). Thus, particular care 
was taken to exclude autofl  uorescent cells and dead cells, and 
to avoid and gate out doublets and aggregates (  Fig. 7 A  ).   Us-
ing this approach, Rag2      /     Il2rg      /      mice were shown to 
have pDCs and cDCs (  Fig. 7 B  ), albeit at reduced total num-
bers compared with wild-type B6 mice (  Fig. 7 E  ). This re-
duction likely refl  ects the absence of B cells (  26  ) and the 
smaller spleen size. Rag2      /     Il2rg      /      mouse spleen appeared 
to contain some CD49b     cells (  Fig. 7 C  ), although this pop-
ulation diff  ered from the CD49b     cells seen in normal B6 
mice (  Fig. 7 C  ). As expected (  25  ), there were virtually no 
CD49b    NK1.1     NK cells in Rag2      /     Il2rg      /      mice (  Fig. 
7 D  ). To enumerate IKDC, we used two separate defi  nitions. 
First, we gated for CD49b    CD11c  int  CD45R     cells and found 
  Figure 7.     IKDCs are severely reduced in Rag2      /     Il2rg      /      mice. Spleens of age- and gender-matched B6 and Rag2     /   Il2rg    /     mice were chopped 
and digested, and lighter density cells were separated using a 1.082-g/cm  3   Nycodenz density cut. Irrelevant cell types were removed, as indicated in the 
Materials and methods. Remaining cells were stained with the following cocktail of fl  uorescently labeled mAbs: anti-CD11c (N418-Cy7-PE), anti-CD45R-
(B220-FITC), anti-NK1.1 (PK136-APC), and anti-CD49b (DX5-biotin, followed by SA-PE secondary; A). Excluded from the analysis were cells that incorpo-
rated PI (indicative of dead cells), had large forward scatter width (indicative of cell doublets), and autofl  uorescent cells (cells that fl  uoresce in the FL4 
channel in the absence of fl  uorochromes that are detected in FL4). (B) DCs in Rag2     /   Il2rg    /     and B6 mice. CD49b     cells (C) or CD49b   NK1.1    cells  (D) 
were gated on and analyzed for CD11c and CD45R expression. (E) The total number of DCs, IKDCs, and NK cells were determined and expressed as the 
ratio of Rag2     /   Il2rg    /     to B6. Three independent experiments were conducted using 3  –  4 Rag2     /   Il2rg    /     and B6 mice. Representative data is presented. 
The ratios of recovered of Rag2     /   Il2rg    /     to B6 cells (E) is the mean of the three experiments, and error bars represent the SEM.     JEM VOL. 204, October 29, 2007 
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at http://www.jem.org/cgi/content/full/jem.20071351/DC1). 
The emerging MHC class II     cells are unlikely to represent a 
contaminating DC population because: (a) DCs do not prolif-
erate under these conditions (  Fig. 9 A  ), and (b) the number of 
cells with up-regulated MHC class II was 10-fold higher than 
the total number of cells initially seeded into culture. 
  Cultured MHC class II     IKDCs do not induce 
T cell proliferation 
  Because some cultured, growth factor  –  expanded IKDCs ex-
pressed MHC class II, in contrast to our CpG activated IKDC, 
we tested their ability to present antigen and activate T cells. 
Day 4 bulk cultures of IKDC containing 10% of MHC class 
II     IKDCs were incubated with OVA peptide and OT-II 
cells. The cultures of IKDC failed to induce considerable 
OT-II cell proliferation compared with DCs at levels equiva-
lent to the number of MHC class II     cells present in the 
IKDC cultures (  Fig. 9 C  ). In addition, cultures of IKDCs and 
NK cells were sorted based on their MHC class II expression, 
and then incubated with whole OVA protein or peptide and 
OT-II cells. Peptide-coated MHC class II     IKDC and NK 
cells induced OT-II proliferation responses that were 100  –
  1,000-fold less effi   cient than that induced by cDCs (  Fig. 9 E  ), 
or by DCs labeled with equivalent levels of anti  –  MHC class II 
mAb. In addition, no response was obtained to whole OVA 
protein (  Fig. 9 F  ). Consistent with the observation that MHC 
class II     IKDCs and NK cells were poor activators of naive 
T cells, these cultured cells did not express signifi  cant levels 
of the costimulatory molecules CD80 and CD86 (  Fig. 9 D  ). 
    DISCUSSION   
  In our DC-enriched preparations, we found cells with the 
reported surface phenotype of IKDCs, namely CD11  int  CD45R   
CD49b    . These cells also expressed the NK cell markers 
NK1.1 and NKG2D. We found that these IKDCs had a 
potent ability to kill NK cell targets, even without preactivation. 
However, in our experiments, the IKDCs had little or no anti-
gen presentation capacity, even after activation. 
  Despite the use of a range of DC activation stimuli (CpG, 
LPS, poly I:C, IL-4, and IFN-    ), and the use of bcl-2 trans-
genic IKDCs to overcome cell death in culture, in our hands, 
the IKDCs failed to up-regulate MHC class II under normal 
conditions of DC activation and failed to activate naive 
antigen-specifi  c T cells, even after incubation with synthetic 
peptide antigen, which is in contrast to an earlier work (  9  ). 
Although much higher levels of peptide were used in the ear-
lier study, we titrated and tested levels of peptide beyond that 
which saturated DC responses, demonstrating that IKDCs 
were 100  –  1,000-fold less effi   cient APCs than DCs. Several 
disease models that might have provided alternate maturation 
signals also failed to induce IKDCs to become APCs. 
  What then is the basis of the diff  erence between our data 
and that of Chan et al. (  9  )? Although the experimental approach 
was similar, there remain some diff  erences in procedures. Selec-
tion of diff  erent types of IKDCs seems unlikely to be the expla-
nation because when we took care to isolate all spleen cells with 
via NKG2D (  8, 9  ). Our overall conclusion was that IKDCs, 
like NK cells, are at a very low level or absent from Rag2      /    
Il2rg      /      mice. 
  Lack of PU.1 expression by IKDCs 
  To further determine whether the gene expression program of 
IKDCs is more closely related to DCs or to NK cells, we ex-
amined the expression of PU.1, which is a transcription factor 
involved in hematopoiesis. PU.1 is not expressed in mature 
NK cells, but is expressed at moderate and high levels in pDCs 
and cDCs, respectively (  28, 29  ). Using the PU.1  gfp   reporter 
mice that express the GFP protein under the control of the 
endogenous PU.1 promoter, we assessed the levels of PU.1 
expression in the IKDCs isolated from our DC preparations 
and compared these to NK cells and DCs. Like mature NK 
cells, these IKDCs failed to express PU.1, although, as ex-
pected, expression was detected in DCs (  Fig. 8  ).   
  Response of IKDCs to NK cell growth factors 
  In our experiments, IKDCs failed to respond to DC growth or 
maturation factors such as CpG and GM-CSF. However, both 
cDCs and pDCs can effi   ciently be generated by culturing bone 
marrow with Flt-3 ligand (  30  ). Thus, we analyzed Flt-3 ligand 
BM cultures for the presence of IKDCs (Fig. S6, available at 
http://www.jem.org/cgi/content/full/jem.20071351/DC1). 
Although both cDCs and pDCs were effi   ciently generated, 
IKDCs were not produced, further delineating the growth 
requirements of these cells from that of DCs. 
  Because IKDCs resembled NK cells by function and many 
surface markers, we tested their response to NK cell growth 
factors. When our IKDCs were cultured in the presence of 
IL-15 and -18, they proliferated extensively, like NK cells, 
whereas DCs did not (  Fig. 9 A  ).   Interestingly, a proportion of 
these expanded IKDCs then expressed surface MHC class II 
(  Fig. 9 B  ). Importantly, a small proportion of expanded NK 
cells also expressed MHC class II (  Fig. 9 B  ); this proportion 
was up to 25% under some culture conditions (Fig. S7, available 
  Figure 8.     IKDCs fail to express the transcription factor PU.1. DCs 
were isolated from PU.1  GFP   and B6 mice, as described in the Materials and 
methods. Enriched DC preparations or a splenic lymphocyte cell suspen-
sion containing NK cells were stained with mAb against CD11c (N418-
Alexa-594), CD45R (B220-Cy7-PE), CD49b (DX5-Biotin, followed by 
SA-PE), and NK1.1 (PK136-APC). The levels of PU.1  GFP   expression on gated 
pDCs (CD11c  int CD45R  CD49b      ), cDCs (CD11c  hi CD45R     CD49b     ),  IKDCs 
(CD11c  int CD45R  CD49b   ), and NK cells (CD49b   NK1.1   ) are represented 
by the solid lines, and B6 backgrounds are represented by the dashed 
lines. Data presented is representative of two experiments.     2586 IKDCS ARE POOR ANTIGEN-PRESENTING CELLS | Caminschi et al.
should have been included in our total spleen IKDC prepara-
tion, which included all spleen CD11c     cells. It may be that the 
beads introduced some additional signals or generated cell dou-
blets between IKDCs and pDCs. However, overlap of their 
IKDC fraction with true APCs is a more likely explanation for 
the IKDC surface phenotype, they showed the same lack of 
T cell stimulation capacity as the IKDC in our DC preparations. 
Another possible diff  erence is the additional use of a positive 
bead selection of CD11c     cells by Chan et al. (  9  ). This may 
have excluded some types of IKDCs, but the selected IKDCs 
  Figure 9.     IKDCs and NK cells proliferate, and a proportion express high levels of class II MHC in response to IL-15 and -18, but do not 
become APCs. Splenic IKDCs (CD11c  int CD45R  CD49b   ), NK cells (NK1.1   CD49b  CD3      ), and DCs (CD11c  hi CD49b      ; 5      10 3   cells) were cultured in 
100     l of media containing 50 ng/ml IL-18 and 50 ng/ml IL-15. At the indicated time points, cells were counted (A), and level of MHC class II was 
determined by staining with M5/114-FITC and analysis by fl  ow cytometry (B). (C) Bulk-cultured IKDCs do not activate OT-II cells. IKDCs were cultured 
as above, harvested on day 4, and determined by fl  ow cytometry to contain 10% MHC class II     cells.  10 4  -cultured IKDCs (containing the equivalent of 
10  3   MHC class II     cells) or 10  3   cells from an enriched DC preparation (DC), were incubated with CFSE-labeled OT-II cells (5      10 4  ) and 1,000 ng/ml of 
class  II – restricted  OVA 323-339   peptide. (D) The levels of the costimulatory markers expressed on cultured MHC class II     and class II        IKDC and NK cells 
compared with fresh cDCs. Expression profi  les were confi  rmed in two independent experiments. (E and F) Purifi  ed MHC class II     IKDCs and NK cells 
were ineffective at inducing OT-II cell proliferation. MHC class II  +   and class II        cultured IKDCs and NK cells, and cDCs (10  4   cells) were incubated with 
CFSE-labeled OT-II cells (5      10 4  ) and graded doses of class II  –  restricted OVA  323-339   peptide (E) or 0.5 mg/ml of whole OVA protein (F) for 4 d. Prolifer-
ating OT-II cells were enumerated as indicated in the Materials and methods. The presented data is representative of three independent experiments. 
Error bars indicate the SEM.     JEM VOL. 204, October 29, 2007 
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but unlike DCs, proliferated vigorously in culture to IL-15 
and -18. 
  Culture of IKDCs in IL-15 and -18 not only induced 
cell proliferation, but produced some cells expressing high 
levels of MHC class II. Importantly, a proportion of cul-
tured NK cells showed a similarly high surface expression 
of MHC class II. To our knowledge, this is the fi  rst study 
of growth factors directly inducing MHC class II expression 
in mouse NK cells and provides some alignment with hu-
man NK cells, which express MHC class II upon activation 
(  19  –  21  ). In addition, mouse NK cells and NKDCs can be 
induced to express MHC class II in vivo (  32  ). These fi  nd-
ings are in contrast to our inability to induce MHC class II 
by activation of IKDC with CpG and other DC stimuli 
in vitro. However, despite the induction of MHC class II, our 
culture-expanded IKDCs did not signifi  cantly up-regulate 
the costimulator molecules CD80 or CD86, and they still 
failed to induce naive T cell proliferation. They could not be 
classed as eff  ective APCs. 
  In conclusion, in our studies, IKDCs resemble NK cells 
in their lytic function, and do not acquire the antigen-
presenting functions of DCs even after activation. As we pre-
viously reported (  10  ), they produce IFN     like NK cells, but 
do not produce IFN     like pDCs. Their transcription factor 
profi  le and response to cytokines resembles that of NK cells, 
not that of DCs. Their developmental relationship to NK 
cells is not entirely clear. They have the appearance of an ac-
tivated form of NK cell, but one study (  31  ) points to diff  er-
ences in early stages of development. In either case, IKDCs 
should be considered as a subtype of NK cells, rather than a 
subtype of DCs. 
    MATERIALS AND METHODS   
  Mice.     C57BL/6J wehi (B6), BALB/c, Rag2      /     Il2rg      /      (backcrossed onto B6), 
and various transgenic mice (vav-bcl-2, PU.1  gfp  , OT-I, OT-I  bm-1  , OT-II, 
DO11.10, CL4, and HNT) were bred under specifi  c pathogen-free con-
ditions at the Walter and Eliza Hall Institute. Female mice were used at 
6    12 wk of age and handled according to the guidelines of the National 
Health and Medical Research Council of Australia. Experimental proce-
dures were approved by the Animal Ethics Committee, Melbourne Health 
Research Directorate. 
  Cell lines and media.     YAC-1 and CHO-K1 cell lines were maintained in 
DME or RPMI-1640 containing 10% FCS, and then harvested during ex-
ponential growth phase for use in assays. Freshly isolated cells were cultured 
in DC culture medium (modifi  ed RPMI-1640 medium containing 10% 
FCS, 100 U/ml penicillin, 100     g/ml streptomycin, and 10      4   M 2-mercap-
toethanol). Where indicated, 50 ng/ml IL-18 (R  &  D Systems) and 50 ng/ml 
IL-15 (rhIL-15; R  &  D Systems) were added to DC culture medium. 
  Antibodies.     The following fl  uorochrome-conjugated mAbs were used: anti-
CD11c (N418)-APC, -Cy5, or -FITC; anti-CD45RA (14.8) or anti-CD45R 
(CD45R; RA-6B2) -PE or -APC; anti-CD49b (DX5)-biotin or -FITC; anti-
NK1.1 (PK136)-biotin or APC; anti-NKG2D (CX5-biotin); anti-MHC class 
II (M5/114)-FITC, PE, or Alexa Fluor 594. For biotin conjugates, streptavi-
din (SA)-PE, SA-Alexa Fluor 594, or SA-Cy7-Pe was used in the second-
stage reaction (BD PharMingen). To assure comparative MHC class II staining, 
our M5/114 conjugates contained suffi   cient unconjugated mAb to saturate 
class II binding, but maintain bright staining on scale. In all staining procedures, 
the diff  erences. One candidate contaminant is CD49b    DC. 
These cells express high levels of MHC class II, CD80, and 
CD86, and thus would be predicted to be potent APCs. 
It is notable that, in the B6 mice we mainly used, these 
CD49b    DCs were at a low level in the DC preparations, but 
their frequency varied in BALB/c DC preparations, on occa-
sions reaching a 1:1 ratio with IKDC. Accordingly, they would 
be harder to exclude from the IKDC fraction. In addition, 
BALB/c mice lack the NK1.1 marker useful for distinguishing 
these two subpopulations. The developmental relationship 
between CD49b    DC and IKDC is not clear, but we obtained 
no transformation of IKDC to CD49b    DC on incubation 
with maturation factors such as CpG. However, it is possible 
that in culture, selective death of IKDCs could masquerade 
as transformation of one into the other, so giving the impres-
sion that IKDCs became eff  ective APCs. A further possible 
contaminant which might lead to induced APC function is 
some residual pDC. We note that the IKDC fraction of Chan 
et al. (  9  ) produced IFN-     on stimulation with CpG. Our recent 
study (  10  ) suggests that pDCs, but not IKDCs, produce IFN-     
under these conditions. 
  An alignment of IKDC with NK cells, rather than with 
DCs, was reinforced by our analysis of the expression of the 
hematopoietic transcription factor PU1. This factor is ex-
pressed at high levels in cDCs and at moderate levels in pDCs, 
but is not expressed on mature NK cells (  28  ). Our IKDCs did 
not express PU.1, aligning their transcription factor expression 
pattern more closely with NK cells. Importantly, IKDC, like 
NK cells, are also dependent on the Id-2 transcription inhibi-
tor, but unlike DCs, they do not express the transcription 
factor Spi-B (  31  ). Therefore, both the cytokine signaling re-
quirements and transcription factor expression profi  les argue 
against a close association of IKDCs and DCs. 
  A compelling argument delineating IKDCs from NK 
cells had been the observation that IKDCs, like DCs, ap-
peared to be present in Rag2      /     Il2rg      /      mice (  8  ), whereas NK 
cells are absent (  25  ). However, our analysis now suggests that 
IKDC cells were markedly reduced, if present at all, in such 
mice. One possible explanation for the discrepancy is the 
disproportionate number of autofl  uorescent cells in DC prepa-
rations from these mice, which may give the false-positive 
signals in the IKDC gates. Multiple markers are required to 
clearly delineate an IKDC population. 
  Responses to growth factors can clarify the lineage rela-
tionships between diff  erent cell types. In our hands IKDCs 
did not respond to the DC growth factor GM-CSF. Admin-
istration of Flt-3 ligand in vivo enhances DC numbers, and 
has been reported to increase a population of   “  NKDCs,  ”   a 
subset of which expresses CD45R, and so might be classed as 
an IKDC. However, our kinetic study of cultures of bone 
marrow with Flt-3 ligand, which effi   ciently generates both 
cDCs and pDCs, indicated that IKDCs were not produced. 
Secondary events of Flt-3 ligand administration may cause 
the elevation of IKDC numbers in vivo. Our GM-CSF and 
Flt-3 ligand culture results suggest IKDC are not respon-
sive to DC growth factors. In contrast, IKDCs, like NK cells, 2588 IKDCS ARE POOR ANTIGEN-PRESENTING CELLS | Caminschi et al.
in DC culture medium with 10 ng/ml GM-CSF and 0.5     M CpG-1668 
(GeneWorks). The level of MHC class II expression by the various DC 
populations was assessed before and 1  –  2 d after activation. 
    51  Chromium release lysis assay.     Purifi  ed eff  ector cells were washed in 
DC culture medium to remove residual EDTA, and then plated in serial 
dilution in U-bottomed 96-well plates in medium with or without GM-CSF 
and CpG. Target cells (YAC-1 or CHO-K1-OVA) were harvested in expo-
nential growth phase, washed, and resuspended in DC culture medium at 
10  7  /ml. 1 million target cells were incubated at 37  °  C for 1.5 h with 100     l 
of sodium chromate (  51  Cr; 100     Ci). Labeled targets were washed 4 times 
and plated at 10  4   cells/well onto prediluted eff  ector cells. Cells were centri-
fuged for 1 min at 335   g   to facilitate cell  –  cell contact, and incubated for 4 h 
at 37  °  C. The plates were centrifuged (for 5 min at 400   g  ), and 100     l of su-
pernatant was removed and counted for 1 min for      emission. Spontaneous 
(S) chromium release was determined by incubating target cells in the ab-
sence of eff  ectors, and maximum (M) cell lysis was obtained by exposing tar-
get cells to 10% Triton X-100. Specifi  c lysis was calculated according to the 
following formula: percentage of lysis = 100   ×   (E      S)/(M      S), where E 
is the experimental chromium release. All eff  ector/target cell ratios were 
conducted in duplicate or triplicate. The spontaneous chromium release was 
routinely   	  10%. 
  Infl  uenza infection of APCs.     For in vitro infections, purifi  ed IKDCs, 
CD49b    DCs, pDCs, cDCs, and NK cells were incubated with 5 PFU/cell 
of PR8 infl  uenza virus for 60 min at 37  °  C. Cells were washed three times, 
and then resuspended in culture media at 1.5   ×   10  5   cells/ml. Graded doses 
of APC were incubated with 50,000 purifi  ed CFSE-labeled HNT or CL4 T 
cells, and after 60 h of coculture, proliferating T cells were enumerated. 
  Malaria infection of mice.     Mice were injected intraperitoneally with 10  6   
  P. berghei   ANKA-infected erythrocytes. Parasitemia was assessed from 
Giemsa-stained smears of tail blood prepared after 2  –  3 d. 3 d after infection, 
spleens were extracted, and DCs, IKDCs, and NK cells were isolated and 
purifi  ed by fl  ow cytometry. 
  Generation of OVA-FLAG expressing CHO cells.     Flag-tagged, mem-
brane-bound OVA (OVA-FLAG) protein was expressed on the surface of 
CHO cells as a C-terminal (extracellular) FLAG-tagged protein. To gener-
ate the FLAG  –  tagged proteins, OVA cDNA was amplifi  ed using Advan-
tage high fi  delity 2 polymerase (CLONTECH Laboratories, Inc.) and the 
primers 5  
  -TAGTAGATGGCGCGCCATGATCAAGCTAGATCAG-
CATTC-3  
   and 5  
  -TAGTAGACGCGTAGGGGAAACACATCTGC-
CAAA-3  
  , using the previously described membrane-bound OVA (fi  rst 118 
amino acids of transferrin receptor linked to amino acids 138  –  385 of OVA) 
(  35  ) as a template. The amplifi  ed cDNA was restriction digested with AscI 
and Mlu-1 and subcloned into the AscI site of a pEF-Bos vector modifi  ed 
to contain the FLAG epitope (donated by T. Willson, Walter and Eliza Hall 
Institute, Melbourne, Australia). CHO cells were cotransfected with the 
pEF-Bos-OVA-FLAG and a pGK-neo plasmid containing the neomycin 
phosphotransferase gene by electroporation (Gene Pulsar; Bio-Rad Lab-
oratories) and transfectants selected with 1 mg/ml G418 (Geneticin; Life 
Technologies). OVA-FLAG  –  positive cells were stained with biotinylated 
anti-FLAG mAb 9H10 (  36  ), followed by SA-PE, and then isolated by fl  ow 
cytometric sorting. 
  Online supplemental material.     Fig. S1 shows that BALB/c IKDCs do 
not activate naive CD4 T cells. Fig. S2 shows that IKDCs preactivated with 
CpG did not acquire APC function. Fig. S3 shows that IKDCs accumulate 
in the spleens of mice infected with malaria. Fig. S4 shows that total spleen 
IKDCs do not activate naive T cells. Fig. S5 shows that parental and Rae-
1      –  expressing RMA-S tumor cells are rejected by NK cells in Rag      /      mice, 
but not by cells in Rag2      /     Il2rg      /      mice. Fig. S6 shows that Flt3 ligand 
bone marrow cultures produce pDCs and cDCs, but not IKDCs. Fig. S7 
blocking with rat Ig anti-Fc receptor mAb (2.4G2) was used to reduce non-
specifi  c staining. 
  Isolation of DC, IKDC, and NK cells.     The isolation of DC subpopulations 
has been previously described (  10, 33, 34  ). In brief, tissues were chopped, 
digested with collagenase and DNase at room temperature, and treated 
with EDTA. Low-density cells were enriched by density centrifugation 
(1.077 g/cm  3   Nycodenz, mouse osmolarity). In some experiments, which 
were designed to select IKDCs from all viable nucleated spleen cells, spleen 
cells were centrifuged instead in 1.091 g/cm  3   Nycodenz medium, eliminat-
ing only the pellet of dead cells and erythrocytes. Non  –  DC lineage cells were 
coated with mAbs (KT3-1.1, anti-CD3; T24/31.7, anti-Thy1; TER119, 
anti-erythrocytes; ID3, anti-CD19; and 1A8, anti-Ly6G or RB6-8C5, anti-
Ly6C/G), and then removed using anti  –  rat Ig magnetic beads (BioMag 
beads; QIAGEN). Coating with RB6-8C5 mAb (anti-Gr-1) did not result 
in the depletion of pDCs (  34  ). In some experiments, anti-Thy1.1 mAb was 
omitted from the depletion mix, and in others only anti-CD3 and -CD19 
were used, without changing the IKDC functional results. Dead cells were 
stained with propidium iodide (PI) and gated out. Freshly isolated splenic DCs 
were fl  uorescent cell sorted based on the expression of CD11c, CD45RA 
(14.8), or CD45R (B220) and CD49b, into CD11c  hi  CD45RA        (cDC), 
CD11c  int  CD45RA    CD49b        (pDC), and CD11  int  CD45RA    CD49b     (IKDC) 
subsets. Splenic NK cells were isolated by chopping and enzymic digestion, 
as mentioned earlier in this section, and removing red and dead cells by 
density centrifugation (1.091 g/cm  3   Nycodenz, mouse osmolarity). Other 
irrelevant cells were then coated with mAbs against MHC class II (M5/114), 
CD24 (M1/69), CD4 (GK1.5), and CD8 (53  –  6.7) and removed using 
anti  –  rat Ig magnetic beads. Remaining cells were stained with mAb against 
CD3    -PE (BD PharMingen), CD49b-FITC, and NK1.1-APC, and NK cells 
(CD49b    NK1.1    CD3       ) were isolated to     99% purity by sorting. Depending 
on the fl  uorochromes used, sorting was performed on a DiVa instrument 
(Becton Dickinson), FACStar Plus (Becton Dickinson), or FACSAria (Becton 
Dickinson), but most commonly on a MoFlo instrument (DakoCytomation); 
the data generated with the sorted populations was consistent between 
instruments. Analysis was performed on LSR1 (Becton Dickinson), FACScan 
(Becton Dickinson), or FACStar Plus instruments. 
  Purifi  cation of transgenic T cells.     CL4 and HNT, OT-I, and OT-II 
transgenic T cells were isolated from lymph node cell suspensions by staining 
irrelevant cells with mAbs (anti-erythrocytes, TER-119; anti-Gr1, RB6-6C5; 
anti-Mac-1, M1/70; anti-class II MHC, M5/114; anti-F4/80, and anti-
CD8, 53  –  6.7; or anti-CD4, GK1.5), and then removing these using anti  –  rat 
Ig  –  coupled magnetic beads at a 1:10 cell/bead ratio; purity was verifi  ed to 
be     95%. 
  CFSE-labeled T cell proliferation assays.     Purifi  ed T cells were washed 
once in 0.1% BSA PBS and resuspended at 10  7   cell/ml. 5 mM CFSE was 
added (1     l/10  7   cells), and incubated at 37  °  C for 10 min. RPMI-1640 me-
dium containing 2.5% FCS was added, and cells were washed twice. T cells 
(5   ×   10  4   cells/well) were incubated with APCs (10  4   cells, or as otherwise 
stated) in U-bottomed 96-well plates in 200     l DC culture medium. Where 
indicated, 10 ng/ml GM-CSF and 0.5     M CpG 1668 were added. Graded 
doses (2  –  2,000 ng/ml) of MHC class II  –  specifi  c OVA peptide (323  –  339) 
or whole OVA (0.5 mg/ml) were added to the cells. To enumerate T cells 
after culture, 2.5   ×   10  4   calibration beads (BD Bioscience) were added 
per well, and T cells were visualized by staining with appropriate markers 
(OT-I or OT-II cells were stained with anti-TCR-V    2 mAb [B20.1-PE; BD 
PharMingen] and HNT or CL4 transgenic T cells were stained with anti-
CD4 [GK1.5-APC] or anti-CD8 [53  –  6.7-APC], respectively). Dead cells were 
excluded using propidium iodide. Analysis was performed on a FACScan or 
FACSCalibur (Becton Dickinson). Proliferating T cells were identifi  ed by 
loss of CFSE fl  uorescence and enumerated relative to the beads, thus allow-
ing a count of total proliferating T cells per well. 
  IKDC and DC activation/maturation.     Isolated DCs and IKDCs (up 
to 10  6   cells/ml) were cultured in U-bottomed 96-well plates for 18  –  44 h JEM VOL. 204, October 29, 2007 
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